CytoSorbents Reports Third Quarter 2023 Financial and Operational Results

PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood

Related Keywords

New Jersey ,United States ,State Of New Jersey ,Germany ,Canada ,New York ,Canadian ,American ,Kathleen Bloch ,James Komsa ,Irina Kulinets ,Vincent Capponi ,Phillip Chan ,Efthymios Deliargyris ,National Institutes Of Health ,National Heart ,Fresenius Medical Care ,Human Services ,Facebook ,Material Command ,Astrazeneca ,Bus Company Contact ,Us Army ,Fresenius ,Cytosorbents Corporation ,Twitter ,Medtronic ,Pfizer ,Vascular Group ,Development Expenses ,European Union ,Us Department Of Health ,Blood Institute ,Us Centers Of Medicare Medicaid Services ,Company Board Of Directors ,Us Air ,Health Canada ,Sorbents Corporation ,Operating Highlights ,Chief Executive Officer ,Timely Antithrombotic Removal ,Safety Monitoring Board ,Global Regulatory ,Device Designation ,Cleveland Clinic ,American Journal ,Cardiovascular Drugs ,Serious Complication ,Quality Star Rating ,Medicaid Services ,Chief Operating Officer ,Chief Medical Officer ,Vice President ,Northeast Cardiac ,Critical Care ,Blood Purification ,Medical Care ,Acute Therapies ,Renal Therapies ,Administrative Expenses ,Foreign Currency Transactions ,Capital Resources ,Call Details ,Presentation Webcast ,Investor Relations ,Use Authorization ,Device Designations ,Timely Antithrombotic Removal Ticagrelor ,National Institutes ,Operations Command ,Air Force Material Command ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Region ,